Skip to main content

23-04-2024 | Circulatory Disease | Editor's Choice | News

ACC 2024

Olezarsen reduces triglyceride levels in patients with hypertriglyceridemia at high CV risk

Author: Dr. Priya Venkatesan

medwireNews: Olezarsen administered monthly for 6 months reduces triglyceride levels by around 57–60% in patients with moderate-to-severe hypertriglyceridemia who are at increased cardiovascular (CV) risk, shows the Bridge–TIMI 73a trial.

Related topics

Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine